We are live on ! Find out more
SFCM

Seven Fleet Capital Management Portfolio holdings

AUM $318M
This Fund
S&P 500
This Quarter Est. Return
+21.73%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$318M
AUM Growth
+$170M
Cap. Flow
+$133M
Cap. Flow %
41.89%
Top 10 Hldgs %
51.26%
Holding
144
New
59
Increased
36
Reduced
17
Closed
29

Top Buys

Rank Stock Value
1
IPSC icon
Century Therapeutics
IPSC
+$6.2M
2
AGIO icon
Agios Pharmaceuticals
AGIO
+$5.04M
3
PCVX icon
Vaxcyte
PCVX
+$4.51M
4
TNGX icon
Tango Therapeutics
TNGX
+$3.99M
5
TYRA icon
Tyra Biosciences
TYRA
+$3.76M

Top Sells

Rank Stock Value
1
CGON icon
CG Oncology
CGON
+$81.6M
2
TERN
Terns Pharmaceuticals
TERN
+$5.27M
3
EXEL icon
Exelixis
EXEL
+$3.01M
4
COGT icon
Cogent Biosciences
COGT
+$2.39M
5
BLTE
Belite Bio
BLTE
+$1.47M

Sector Composition

Rank Sector Weight
1 Healthcare 55.86%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EWTX icon
76
Edgewise Therapeutics
EWTX
$4.7B
$369K 0.12%
11,701
+9,701
+485% +$280K
UNCY icon
77
Unicycive Therapeutics
UNCY
$145M
$367K 0.12%
+55,700
New +$365K
CTNM
78
Contineum Therapeutics
CTNM
$592M
$353K 0.11%
+27,054
New +$363K
TRVI icon
79
Trevi Therapeutics
TRVI
$2.55B
$324K 0.1%
27,149
+20,039
+282% +$224K
EOLS icon
80
Evolus
EOLS
$548M
$321K 0.1%
78,057
-3,943
-5% -$19.1K
NKTR icon
81
Nektar Therapeutics
NKTR
$2.6B
$309K 0.1%
4,300
-10,700
-71% -$609K
FULC icon
82
Fulcrum Therapeutics
FULC
$280M
$292K 0.09%
+38,100
New +$353K
SEPN
83
Septerna Inc
SEPN
$2.21B
$275K 0.09%
11,445
– –
OCUL icon
84
Ocular Therapeutix
OCUL
$2.26B
$265K 0.08%
31,296
+14,196
+83% +$135K
ZNTL icon
85
Zentalis Pharmaceuticals
ZNTL
$312M
$257K 0.08%
+110,000
New +$284K
AMLX icon
86
Amylyx Pharmaceuticals
AMLX
$2.61B
$232K 0.07%
16,671
+5,100
+44% +$71.7K
ENTX icon
87
Entera Bio
ENTX
$143M
$228K 0.07%
205,542
+70,224
+52% +$98.5K
NUVL
88
DELISTED
Nuvalent
NUVL
$212K 0.07%
2,072
-10,529
-84% -$1.07M
BEAM icon
89
Beam Therapeutics
BEAM
$2.75B
$210K 0.07%
8,804
-733
-8% -$20.3K
IRON icon
90
Disc Medicine
IRON
$3.09B
$207K 0.06%
+3,231
New +$224K
WHWK
91
Whitehawk Therapeutics
WHWK
$271M
$187K 0.06%
+54,296
New +$170K
INBX icon
92
Inhibrx
INBX
$1.46B
$167K 0.05%
+2,482
New +$184K
APGE icon
93
Apogee Therapeutics
APGE
$10.2B
$166K 0.05%
1,969
+169
+9% +$12.3K
CCCC icon
94
C4 Therapeutics
CCCC
$482M
$150K 0.05%
+57,076
New +$134K
PMN icon
95
ProMIS Neurosciences
PMN
$130M
$135K 0.04%
+10,600
New +$158K
PEPG icon
96
PepGen
PEPG
$199M
$105K 0.03%
+59,500
New +$334K
PMVP icon
97
PMV Pharmaceuticals
PMVP
$68.3M
$78.7K 0.02%
63,498
– –
MGNX icon
98
MacroGenics
MGNX
$270M
$38.7K 0.01%
+13,387
New +$28.6K
CGEM icon
99
Cullinan Oncology
CGEM
$1.27B
$26.2K 0.01%
1,844
-1,156
-39% -$14.9K
ACRS icon
100
Aclaris Therapeutics
ACRS
$866M
– –
-107,419
Closed -$323K
2 3
4
5 6

Similar funds

SA
SAM Advisors Oakhurst, California $319M AUM 17.08% 1-Year Est. Return
KI
Keewaydin Investments Southampton, New York $317M AUM
CPH
C Partners Holding Zurich, Switzerland $317M AUM 4.76% 1-Year Est. Return
FNWM
Financial Network Wealth Management Draper, Utah $316M AUM
MJFG
Mars Jewett Financial Group Bellevue, Washington $316M AUM
KC
KHIS Custodian Dallas, Texas $316M AUM
EC
Edenbrook Capital Mt. Kisco, New York $321M AUM 79.21% 1-Year Est. Return
WA
Waterford Advisors Orchard Park, New York $315M AUM 15.21% 1-Year Est. Return

Seven Fleet Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, Seven Fleet Capital Management held 144 positions worth $318M, up 115% from $148M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Seven Fleet Capital Management deployed $133M of net new capital in Q1 2026, opening 59 new positions and adding to 36 existing holdings. Its largest new stake was Century Therapeutics: 2,947,826 shares worth $6.66M.

By sector, the portfolio is most concentrated in Healthcare at 56% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was CG Oncology, an estimated $81.6M trimmed.

  • Seven Fleet Capital Management's largest Q1 2026 buy was Century Therapeutics: 2,947,826 shares worth $6.66M.
  • Seven Fleet Capital Management added most to Agios Pharmaceuticals in Q1 2026, an estimated $5.04M increase.
  • Seven Fleet Capital Management's biggest Q1 2026 reduction was CG Oncology, cutting an estimated $81.6M.
  • Seven Fleet Capital Management fully exited Terns Pharmaceuticals in Q1 2026, selling an estimated $5.27M.
  • Seven Fleet Capital Management's ten largest holdings make up 51% of its $318M portfolio in Q1 2026.
  • Seven Fleet Capital Management opened 59 new positions and closed 29 in Q1 2026.
  • Seven Fleet Capital Management's portfolio value rose 115% quarter-over-quarter to $318M.

Based on Seven Fleet Capital Management's 13F filing for Q1 2026, filed 15 May 2026.